NewsMV
NRx Defense Systems, a subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), has been awarded an initial contract valued at $11,177,757.27 by the Defense Advanced Research Projects Agency.
The funding supports the Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC-TMS) trial, which is approved by the US Food and Drug Administration and will begin enrolling patients.
The trial aims to evaluate whether a single day of robotic neuronavigated Transcranial Magnetic Stimulation (TMS), augmented by the investigational drug NRX-101, can effectively treat major depressive disorder.
DARPA states that if the program succeeds, it will fundamentally change the standard of care for treatment-resistant depression, addressing military concerns that current treatments are not deployable in operational settings.
Keep reading